The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches.
Open accessThe DOI matches its OpenAlex record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The HER family of receptor tyrosine kinase couples binding of extracellular growth factor ligands to intracellular signal transduction pathways, contributing in this fashion to the ability of the cell to respond correctly to its environment. The HER family and its ligands are critically involved in the carcinogenesis of the mammary gland. Abnormal function of the members of HER family resulting in receptor hyper-activation (due to gene amplification, protein overexpression or abnormal transcriptional regulation) has been linked with breast cancer prognosis. It is also extensively studied as the predictive factor and target for therapy. There are clinical indications supporting the concept that none of the receptors: EGFR, HER2, HER3 and HER4 can be considered as the stand-alone receptor in breast cancer development and clinical course of the disease. There is a growing body of evidence that cooperation between them contributes to more aggressive tumor phenotype and influences the response to therapy. This underlines the importance of quantification of all HER family members and indicates the urgent need for implementation of methods that can efficiently and reliably examine four HER receptors as a whole panel in breast cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial control of cell death
Kroemer, G., & Reed, J. C. (2000) · Nature Medicine · doi:10.1038/74994 · Cited by 3,103
Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., Kaye, S. B., Gianni, L., Harris, A., Bjork, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.100 · Cited by 829
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.
Guy, P. M., Platko, J. V., Cantley, L. C., Cerione, R. A., & Carraway, K. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.17.8132 · Cited by 698 · cited 2×
“Further complexity to the signaling network is added due to the existence of an oncogenic receptor that enhances and stabilizes dimerization but has no ligand (HER2) (Klapper et al., 1999), and a receptor that can recruit novel proteins, but lacks kinase activity (HER3) (Guy et al., 1994).”
BackgroundKlapper, L. N., Glathe, S., Vaisman, N., Hynes, N. E., Andrews, G. C., Sela, M., & Yarden, Y. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4995 · Cited by 455 · cited 2×
“Further complexity to the signaling network is added due to the existence of an oncogenic receptor that enhances and stabilizes dimerization but has no ligand (HER2) (Klapper et al., 1999), and a receptor that can recruit novel proteins, but lacks kinase activity (HER3) (Guy et al.”
BackgroundHeregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.
Wallasch, C., Weiss, F. U., Niederfellner, G., Jallal, B., Issing, W., & Ullrich, A. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00101.x · Cited by 406
Signal transduction and oncogenesis by ErbB/HER receptors
Marmor, M. D., Skaria, K. B., & Yarden, Y. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.06.002 · Cited by 389
Cited by
Sabbah, D. A., Hajjo, R., & Sweidan, K. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200303123102 · Cited by 591
Epidermal growth factor receptor targeting in cancer: a review of trends and strategies
Yewale, C., Baradia, D., Vhora, I., Patil, S., & Misra, A. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.07.100 · Cited by 533
Sahin, Ö., Fröhlich, H., Löbke, C., Korf, U., Burmester, S., Majety, M., Mattern, J., Schupp, I., Chaouiya, C., Thieffry, D., et al. (2009) · BMC Systems Biology · doi:10.1186/1752-0509-3-1 · Cited by 335
EGFR amplification and lack of activating mutations in metaplastic breast carcinomas
Reis‐Filho, J., Pinheiro, C., Lambros, M., Milanezi, F., Carvalho, S., Savage, K., Simpson, P., Jones, C., Swift, S., Mackay, A., et al. (2006) · The Journal of Pathology · doi:10.1002/path.2004 · Cited by 266
Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer
Zhang, X. L., Yang, Y. S., Xu, D. P., Qu, J. H., Guo, M. Z., Gong, Y., & Huang, J. (2009) · World Journal of Surgery · doi:10.1007/s00268-009-0142-z · Cited by 165
Metadata
- Authors
- Zaczek, A. J., Brandt, B., & Bielawski, K. P.
- Venue
- PubMed
- Publisher
- National Institutes of Health
- Published
- 2005-07-01
- Volume
- 20
- Issue
- 3
- Pages
- 1005-15
- OpenAlex
- W101171352
- Cited by
- 127
- References
- 6
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. https://app.cochat.ai/papers/10.14670/hh-20.1005
- The paper
- Zaczek, A. J., Brandt, B., & Bielawski, K. P. (2005). The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. PubMed. https://doi.org/10.14670/hh-20.1005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.